Equities research analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings per share of ($0.31) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Acorda Therapeutics’ earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.45). Acorda Therapeutics reported earnings of ($0.46) per share during the same quarter last year, which indicates a positive year over year growth rate of 32.6%. The business is scheduled to issue its next earnings report on Monday, November 2nd.
On average, analysts expect that Acorda Therapeutics will report full-year earnings of ($1.64) per share for the current financial year, with EPS estimates ranging from ($1.83) to ($1.45). For the next year, analysts anticipate that the business will report earnings of ($1.84) per share, with EPS estimates ranging from ($2.50) to ($1.00). Zacks’ EPS calculations are an average based on a survey of analysts that cover Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.27. Acorda Therapeutics had a negative net margin of 138.66% and a negative return on equity of 19.55%.
ACOR traded up $0.04 during midday trading on Wednesday, hitting $0.55. The stock had a trading volume of 1,533,653 shares, compared to its average volume of 2,135,289. The company has a market cap of $21.73 million, a P/E ratio of -0.12 and a beta of 1.46. The business has a fifty day moving average of $0.60 and a 200 day moving average of $0.83. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.90 and a current ratio of 1.14. Acorda Therapeutics has a 1 year low of $0.42 and a 1 year high of $3.75.
Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its stake in shares of Acorda Therapeutics by 571.7% in the first quarter. Royal Bank of Canada now owns 32,826 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 27,939 shares during the period. JPMorgan Chase & Co. grew its holdings in Acorda Therapeutics by 153.4% during the 1st quarter. JPMorgan Chase & Co. now owns 539,339 shares of the biopharmaceutical company’s stock valued at $502,000 after buying an additional 326,530 shares in the last quarter. Blair William & Co. IL purchased a new position in Acorda Therapeutics during the 2nd quarter valued at approximately $39,000. GSA Capital Partners LLP purchased a new position in Acorda Therapeutics during the 1st quarter valued at approximately $233,000. Finally, State Street Corp grew its holdings in Acorda Therapeutics by 1.6% during the 1st quarter. State Street Corp now owns 1,492,994 shares of the biopharmaceutical company’s stock valued at $1,392,000 after buying an additional 23,906 shares in the last quarter. 50.14% of the stock is currently owned by institutional investors.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
Recommended Story: Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.